Uniqure B.V. buy melinda
Start price
27.06.17
/
50%
€5.41
Target price
18.07.17
€6.13
Performance (%)
7.52%
End price
18.07.17
€5.82
Summary
This prediction ended on 18.07.17 with a price of €5.82. The BUY prediction by melinda finished with a performance of 7.52%. melinda has a follow-up prediction for Uniqure B.V. where he still thinks Uniqure B.V. is a Buy. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Uniqure B.V. | 0.810% | 0.810% | 193.401% | 260.521% |
| iShares Core DAX® | -2,68 % | 4,26 % | 2,12 % | 57,51 % |
| iShares Nasdaq 100 | 0,73 % | 5,80 % | 34,20 % | 92,83 % |
| iShares Nikkei 225® | -0,73 % | 9,32 % | 61,30 % | 80,34 % |
| iShares S&P 500 | 1,17 % | 5,48 % | 24,75 % | 70,97 % |
According to melinda what are the pros and cons of Uniqure B.V. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Uniqure B.V. diskutieren
Gesundheit | Biotechnologie | Niederlande
Aktualisiert Phase 1/2 nach dem Kongress der Internationalen Gesellschaft für Thrombose und Hämostase (ISTH) 2017, die 11. Juli 2017. Phase - 2b - Studie zu Q3 2017 beginnen.
Current prediction by melinda for Uniqure B.V.
Uniqure B.V.
Start price
Target price
Perf. (%)
€14.71
13.03.26
13.03.26
-
13.03.27
13.03.27
153.91%
10.07.26
10.07.26
Could be worthwhile Investment >10% per year
Stopped prediction by melinda for Uniqure B.V.
Uniqure B.V.
Start price
Target price
Perf. (%)
€19.00
27.12.21
27.12.21
-
27.12.22
27.12.22
8.55%
28.12.22
28.12.22
Could be worthwhile Investment >10% per year
Uniqure B.V.
Start price
Target price
Perf. (%)
€32.45
29.08.20
29.08.20
€40.00
04.11.21
04.11.21
-7.18%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Uniqure B.V.
Start price
Target price
Perf. (%)
€38.10
30.08.18
30.08.18
€40.59
25.02.19
25.02.19
31.53%
25.02.19
25.02.19
Could be worthwhile Investment >10% per year